ADJUVANT THERAPY
Clinical trials for ADJUVANT THERAPY explained in plain language.
Never miss a new study
Get alerted when new ADJUVANT THERAPY trials appear
Sign up with your email to follow new studies for ADJUVANT THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to stop High-Risk breast cancer from coming back
Disease control Recruiting nowThis study tests whether adding a CDK4/6 inhibitor to standard hormone therapy can help prevent breast cancer from returning in women with a high-risk, hormone receptor-positive and HER2-positive early breast cancer who have already completed anti-HER2 treatment. About 1,900 wome…
Matched conditions: ADJUVANT THERAPY
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
Experimental 'Armored' cell shot targets solid cancers in tiny safety trial
Disease control Recruiting nowThis early study is testing a single injection of special immune cells (dendritic cells) that are 'armored' with antibodies to see if they are safe for people with solid tumors like pancreatic, colorectal, or stomach cancer. Only 8 adults who have already had surgery and chemothe…
Matched conditions: ADJUVANT THERAPY
Phase: PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
New study aims to get cancer patients moving during treatment
Symptom relief Recruiting nowThis study tests whether a digital support program can help people with breast, prostate, or colorectal cancer reduce the time they spend sitting during their treatment. The goal is to improve their well-being and lower future health risks. About 172 participants will be randomly…
Matched conditions: ADJUVANT THERAPY
Phase: NA • Sponsor: Mälardalen University • Aim: Symptom relief
Last updated May 26, 2026 03:11 UTC
-
New study tracks breast cancer relapses after modern drug therapy
Knowledge-focused Recruiting nowThis study looks at 750 breast cancer patients whose cancer came back after they received CDK4/6 inhibitors (ribociclib or abemaciclib) along with hormone therapy. Researchers want to understand the features of these relapsed cancers and how patients fare afterward. The study doe…
Matched conditions: ADJUVANT THERAPY
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated May 26, 2026 03:23 UTC